K Yurko-Mauro

Summary

Publications

  1. ncbi Memory improvement with docosahexaenoic acid Study (MIDAS)--brief review
    Karin Yurko-Mauro
    Clinical Research, Martek Biosciences Corporation, 6480 Dobbin Rd, Columbia, MD 21045, USA
    Curr Alzheimer Res 4:553-5. 2007
  2. ncbi Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline
    K Yurko-Mauro
    Clinical Research, Martek Biosciences Corporation, Columbia, MD 21045, USA
    Curr Alzheimer Res 7:190-6. 2010
  3. ncbi Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
    Karin Yurko-Mauro
    Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    Alzheimers Dement 6:456-64. 2010

Collaborators

Detail Information

Publications3

  1. ncbi Memory improvement with docosahexaenoic acid Study (MIDAS)--brief review
    Karin Yurko-Mauro
    Clinical Research, Martek Biosciences Corporation, 6480 Dobbin Rd, Columbia, MD 21045, USA
    Curr Alzheimer Res 4:553-5. 2007
  2. ncbi Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline
    K Yurko-Mauro
    Clinical Research, Martek Biosciences Corporation, Columbia, MD 21045, USA
    Curr Alzheimer Res 7:190-6. 2010
    ..Collectively, data reveal a potentially beneficial role for DHA in preventing or ameliorating cognitive decline and cardiovascular disease in the aged...
  3. ncbi Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
    Karin Yurko-Mauro
    Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    Alzheimers Dement 6:456-64. 2010
    ..Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age-related cognitive decline (ARCD) have not been fully examined...